Vergelijking van een enkele versus dubbele Perclose-techniek voor TAVR (Single)
Het gebruik van enkele versus dubbele Perclose-apparaten voor transfemorale aortaklepvervanging Toegangsplaatssluiting: een prospectief, multicenter, gerandomiseerd gecontroleerd onderzoek
Transcatheter aortic valve replacement (TAVR) has become widely recognized as a minimally invasive approach for aortic valve replacement in patients with severe aortic stenosis. It has been proven to be a safe and effective option for patients who are at low, intermediate, and prohibitive risk for surgical valve replacement.
One of the critical components of procedural success in a transfemoral approach is access site management, as vascular complications strongly correlate with adverse outcomes. When major vascular complications occur, there are higher rates of major bleeding, transfusions, and renal failure requiring dialysis, as well as a significantly higher rate of 30-day and 1-year mortality. In recent years, a "preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site. This allows for arterial closure after dilation to sizing up to larger bore access sheaths that accommodate valve delivery systems. The sutures are subsequently harvested and tightened to close the large bore arteriotomy site at the end of the case. It has been demonstrated that the use of two Perclose devices, or double Perclose closure, is an effective closure technique with a low rate of vascular complications. A large number of TAVR centers have adopted this method for large-bore vascular closure. In the past, there have been few investigations comparing the utilization of a single Perclose device compared to a double Perclose technique. There are numerous theoretical advantages to the use of a single device, which include decreased procedural cost and procedural time. The investigation aimed to determine if there are clinical benefits as well using the single Perclose approach.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
SINGLE-CLOSURE (The utilization of Single versus double perclose devices for transfemoral aortIc valve replacement access site Closure) is an investigator-initiated, open-label, multicenter, randomized controlled trial. The study was approved by the local ethics committees of all participating centers, and each patient provided written informed consent for inclusion in the trial. Data management and analysis was performed by an independent data coordinating center, with oversight from a steering committee. The members of the steering committee had full access to the data and vouch for the accuracy and complete- ness of the data and the analyses. The data that support the findings of this study are available from the corresponding author on reasonable request. Patients scheduled to undergo transfemoral TAVR were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. Inclusion criteria were an indication for TAVR as judged by the local heart team; selection of the transfemoral access route and a commercially available transcatheter aortic valve; and willingness to comply with protocol specified follow-up evaluations. Principal exclusion criteria were a vascular access site anatomy not suitable for percutaneous vascular closure and the occurrence of vascular access site complications before the TAVR procedure. Additional exclusion criteria were a known allergy or hypersensitivity to any VCD component; unstable active bleeding or bleeding diathesis or significant unman-ageable anemia; absence of computed tomographic data of the access site before the procedure; systemic infection or a local infection at or near the access site; life expectancy of <6 months because of noncardiac conditions; patients who cannot adhere to or complete the investigational protocol for any reason; pregnant or nursing patients; and participation in any other interventional trial.
The primary end point of the trial was the rate of access site or access-related major and minor vascular complications defined according to the Valve Academic Research Consortium-3 criteria. The end point was assessed during index hospitalization. Relationship to the access site was deter- mined according to the site used for the large-bore vascular access sheath.
Secondary end points included the rate of the primary end point at 30 days; components of the primary end point in-hospital and at 30 days; in-hospital and 30-day major and minor vascular complications; unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site; in-hospital and 30-day access site- or access-related minor, major, and disabling or life threatening bleeding; need for blood transfusion for access site- or access-related bleeding or vascular complications; rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning); in-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site or access-related complications; need and number of additional unplanned VCDs; time to hemostasis, defined as the time from VCD application to complete hemostasis; and the length of postprocedural hospital stay.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Beijing, China
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
Beijing, China
- Beijing Anzhen Hospital, Capital Medical University
-
-
Anhui
-
Bengbu, Anhui, China
- The First Affiliated Hospital of Bengbu Medical College
-
-
Fujian
-
Fuzhou, Fujian, China
- Fujian Provincial Hospital
-
-
Gansu
-
Lanzhou, Gansu, China
- The First Hospital of Lanzhou University
-
-
Guangdong
-
Guangzhou, Guangdong, China
- The First Affiliated Hospital, Sun Yat-sen University
-
Guangzhou, Guangdong, China
- Nanfang Hospital, Southern Medical University
-
Zhanjiang, Guangdong, China
- The Affiliated Hospital of Guangdong Medical University
-
-
Guangxi
-
Yulin, Guangxi, China
- Yulin First People's Hospital
-
-
Henan
-
Changshacun, Henan, China
- Xiangya Hospital of Central South University
-
Zhengzhou, Henan, China
- Fuwai Central China Cardiovascular Hospital
-
Zhengzhou, Henan, China
- Henan Provincial Chest Hospital
-
-
Hunan
-
Changsha, Hunan, China
- The Second Xiangya Hospital of Central South University
-
-
Liaoning
-
Shenyang, Liaoning, China
- General Hospital of Northern Theater Command, PLA
-
-
Shandong
-
Jinan, Shandong, China
- Qilu Hospital of Shandong University
-
Qingdao, Shandong, China
- The Affiliated Hospital of Qingdao University
-
Qingdao, Shandong, China
- Qingdao Municipal Hospital
-
-
Shanxi
-
Xi’an, Shanxi, China
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, China
- Sichuan Provincial People's Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, China
- People's Hospital of Xinjiang Uygur Autonomous Region
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University
-
Huzhou, Zhejiang, China
- Huzhou Central Hospital
-
Ningbo, Zhejiang, China
- The First Affiliated Hospital of Ningbo University
-
Ningbo, Zhejiang, China
- Ningbo Medical Center Li Huili Hospital
-
Wenzhou, Zhejiang, China
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients scheduled to undergo transfemoral TAVR were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. Inclusion criteria were an indication for TAVR as judged by the local heart team; selection of the transfemoral access route and a commercially available transcatheter aortic valve; and willingness to comply with protocol specified follow-up evaluations.
Exclusion Criteria:
- Principal exclusion criteria were a vascular access site anatomy not suitable for percutaneous vascular closure and the occurrence of vascular access site complications before the TAVR procedure. Additional exclusion criteria were a known allergy or hypersensitivity to any VCD component; unstable active bleeding or bleeding diathesis or significant unman ageable anemia; absence of computed tomographic data of the access site before the procedure; systemic infection or a local infection at or near the access site; life expectancy of <6 months because of noncardiac conditions; patients who can-not adhere to or complete the investigational protocol for any reason; pregnant or nursing patients; and participation in any other interventional trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Double Perclose device
Double Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures |
"Preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site. |
|
Experimenteel: Single Perclose device
Single Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures |
"Preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The primary end point of the trial was the rate of access site or access-related major and minor vascular complications defined according to the Valve Academic Research Consortium-3 criteria
Tijdsspanne: The end point was assessed during index hospitalization
|
|
The end point was assessed during index hospitalization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The rate of the primary end point at 30 days
Tijdsspanne: 30 days
|
the rate of access site or access-related major and minor vascular complications at 30 days |
30 days
|
|
Components of the primary end point in-hospital and at 30 days
Tijdsspanne: 30 days
|
Components of the rate of access site or access-related major and minor vascular complications at 30 days |
30 days
|
|
In-hospital and 30-day major and minor vascular complications
Tijdsspanne: 30 days
|
In-hospital and 30-day major and minor vascular complications |
30 days
|
|
Unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site
Tijdsspanne: 30 days
|
Unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site at 30 days |
30 days
|
|
in-hospital and 30-day access site- or access-related minor, major, and disabling or life- threatening bleeding; need for blood transfusion for access site or access related bleeding or vascular complications
Tijdsspanne: 30 days
|
in-hospital and 30-day access site- or access-related minor, major, and disabling or life- threatening bleeding; need for blood transfusion for access site or access related bleeding or vascular complications |
30 days
|
|
Rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning)
Tijdsspanne: 30 days
|
Rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning) at 30 days |
30 days
|
|
In-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site- access-related complications; need and number of additional unplanned VCDs
Tijdsspanne: 30 days
|
In-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site- access-related complications; need and number of additional unplanned VCDs |
30 days
|
|
Time to hemostasis, defined as the time from VCD application to complete hemostasis
Tijdsspanne: 30 days
|
Time to hemostasis, defined as the time from VCD application to complete at 30 days |
30 days
|
|
The length of postprocedural hospital stay
Tijdsspanne: 30 days
|
The length of postprocedural hospital stay |
30 days
|
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: Jianan Wang, PhD, Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- SAHZJU CT022
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .